financetom
Business
financetom
/
Business
/
Phillips 66 Posts Strong Q3 Results With Marketing, Chemicals Driving Gains
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Phillips 66 Posts Strong Q3 Results With Marketing, Chemicals Driving Gains
Oct 29, 2024 8:46 PM

Phillips 66 shares are trading lower on Tuesday after it reported third-quarter FY24 results.

Midstream segment adjusted pre-tax income stood at $672 million, vs. $753 million in the second quarter of FY24, owing to seasonal maintenance costs and lower equity earnings.

The Chemicals segment adjusted pre-tax income stood at $342 million versus $222 million in the prior quarter, led by higher margins and lower costs.

The Refining segment adjusted pre-tax income stood at $(67) million versus $302 million in the prior quarter due to weak realized margins on lower market crack spreads.

The Marketing and Specialties segment adjusted pre-tax income rose to $583 million from $415 million in the prior quarter on higher margins.

Adjusted EPS of $2.04 topped the consensus of $1.66.

The company reported refining operations with 94% crude capacity utilization and 87% clean product yield.

Phillips 66 reported operating cash flow, excluding working capital impacts, of $1.51 billion. 

As of September 30, the company reported cash and cash equivalents of $1.6 billion, along with $5.3 billion in committed credit facility capacity.

Since July 2022, the company has distributed $12.5 billion through share repurchases and dividends and is on pace to achieve its $13 billion to $15 billion target by year-end.

Phillips 66 achieved $1.4 billion in run-rate cost savings in the quarter.

Investors can gain exposure to the stock via IShares U.S. Oil & Gas Exploration & Production ETF ( IEO ) and VanEck Oil Refiners ETF ( CRAK ) .

Price Action: PSX shares are down 1.75% at $126.63 at last check Tuesday.

Read Next:

Dow Surges Over 250 Points Ahead Of Alphabet, Pfizer Earnings: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Endava Fiscal Q4 Adjusted Earnings Down, Revenue Up; Fiscal Q1, 2025 Earnings, Revenue Outlook Issued
Endava Fiscal Q4 Adjusted Earnings Down, Revenue Up; Fiscal Q1, 2025 Earnings, Revenue Outlook Issued
Sep 22, 2024
08:01 AM EDT, 09/19/2024 (MT Newswires) -- Endava ( DAVA ) reported fiscal Q4 adjusted earnings Thursday of 0.22 British pounds ($0.29) per diluted share, down from 0.57 pounds a year earlier. Analysts polled by Capital IQ expected 0.23 pounds. Revenue for the quarter ended June 30 was 194.4 million pounds, up from 189.8 million a year earlier. Analysts surveyed...
Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment
Achilles Therapeutics Discontinues cNeT Program and Closes Early-to-Mid Stage Studies For Cancer Treatment
Sep 22, 2024
08:04 AM EDT, 09/19/2024 (MT Newswires) -- Achilles Therapeutics ( ACHL ) said Thursday that it is discontinuing its TIL-based cNeT program and closing the phase I/II clinical trials for non-small cell lung cancer treatment. The company said it would change its strategy to pursue partnerships with third parties developing alternative treatments for clonal neoantigens, such as neoantigen vaccines, ADCs,...
US transport chief says he's optimistic for Boeing labor resolution
US transport chief says he's optimistic for Boeing labor resolution
Sep 22, 2024
WASHINGTON (Reuters) - U.S. Transportation Secretary Pete Buttigieg on Thursday said he believes both sides want to reach an agreement in the labor dispute at Boeing ( BA ) in which 30,000 striking machinists have halted production of its best-selling 737 MAX and other airplanes. I do believe that both parties want to get to a resolution here, and hoping...
Aligos' fatty liver disease treatment meets main goal in mid-stage study
Aligos' fatty liver disease treatment meets main goal in mid-stage study
Sep 22, 2024
Sept 19 (Reuters) - Aligos Therapeutics ( ALGS ) said on Thursday its experimental treatment for a serious type of fatty liver disease helped significantly reduce liver fat, meeting the main goal of a mid-stage study. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved